IL-6 as a biomarker of ischemic cerebrovascular disease

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• A rapid diagnostic tool for stroke is lacking, hindering optimal patient care.
• Inflammation, particularly involving proinflammatory cytokines like IL-6, plays a significant role in ischemic cerebrovascular disease.
• IL-6's role in acute stroke pathophysiology, including potential promotion of ischemic brain injury and neurological worsening, requires further investigation.

Purpose of the Study:

• To evaluate Interleukin-6 (IL-6) as a biochemical marker for stroke diagnosis.
• To investigate the genetic basis and protein changes of IL-6 in serum and cerebrospinal fluid concerning stroke development.
• To explore the association between IL-6 and stroke, considering its potential role in disease susceptibility and progression.

Main Methods:

• Analysis of IL-6 protein levels in serum and cerebrospinal fluid.
• Investigation of the -174 G/C functional polymorphism in the IL-6 gene.
• Correlation of IL-6 levels and genetic variations with stroke diagnosis, severity, and clinical worsening.

Main Results:

• IL-6 levels in cerebrospinal fluid and serum appear to correlate with the extent of tissue damage and clinical worsening in stroke patients.
• The -174 G/C functional polymorphism in the IL-6 gene's direct association with stroke susceptibility remains undetermined.
• Evidence suggests IL-6 may be in linkage disequilibrium with other functional polymorphisms, complicating direct genotype-stroke association.

Conclusions:

• IL-6 shows potential as a biomarker for assessing stroke severity and predicting neurological decline.
• Further research is necessary to fully elucidate the genetic underpinnings of IL-6's involvement in stroke.
• Targeting IL-6-mediated inflammation presents a promising therapeutic strategy for preventing early deterioration in acute ischemic stroke.